… Since the last published Canadian Thoracic Society (CTS) position statement on the
pharmacotherapy in patients with chronic obstructive pulmonary disease (COPD) in 2017,Citation 1 …

… During night-time, in COPD patients the supine position is responsible for a different …
Moreover, in COPD patients the circadian rhythm may be impaired. The role of pharmacotherapy in …

… This position paper uses combined classification including COPD stages (1 to 4), COPD
groups (… Current opinions: Inhaled medications are the cornerstone of COPD pharmacotherapy. …

… , pharmacotherapy for COPD should be actively utilized in the course of treatment. The
main purpose of COPD … In recent decades, much more new therapies have been developed …

… , diagnosis, and pharmacotherapy of COPD have been … classification of LMWDs for COPD
treatment in medicinal chemistry… a ZBG and the 4-position on the phenyl substituted by alkynyl …

… Some phase 4 RCTs provide interesting information on how best to position LAMA/LABA
combinations in treating COPD ( Table 2 ). Unfortunately, however, few direct comparisons …

… source for prescribing inhaled therapies for individuals with COPD (6) . The GOLD program
… guidelines on pharmacotherapy for patients with COPD (7, 8) . Experts on COPD in Spain …

… deletion in exon 10 for phenylalanine at position 508 (p.Phe508del) in the … pharmacotherapy
of chronic obstructive respiratory disorders such as human and equine asthma and COPD, …

… Existing healthcare policies should be revisited to include COPD prevention and … position
statements that should be implemented as a consistent standard of care for patients with COPD…

… A collaboration of the pulmonary rehabilitation programme with patient education and
pharmacotherapy significantly improves patients’ quality of life. An RCT in Canada reported a 40% …